Abstract:Human microbiomes, particularly in the gut, could have a major impact on the efficacy and toxicity of drugs. However, gut microbial metabolism is often neglected in the drug discovery and development process. Medicen, a Paris-based human health innovation cluster, has gathered more than 30 international leading experts from pharma, academia, biotech, clinical research organizations, and regulatory science to develop proposals to facilitate the integration of microbiome science into drug discovery and development. Seven subteams were formed to cover the complementary expertise areas of 1) pharma experience and case studies, 2) in silico microbiome–drug interaction, 3) in vitro microbial stability screening, 4) gut fermentation models, 5) animal models, 6) microbiome integration in clinical and regulatory aspects, and 7) microbiome ecosystems and models. Each expert team produced a state-of-the-art report of their respective field highlighting existing microbiome-related tools at every stage of drug discovery and development. The most critical limitations are the growing, but still limited, drug–microbiome interaction data to produce predictive models and the lack of agreed-upon standards despite recent progress. In this paper we will report on and share proposals covering 1) how microbiome tools can support moving a compound from drug discovery to clinical proof-of-concept studies and alert early on potential undesired properties stemming from microbiome-induced drug metabolism and 2) how microbiome data can be generated and integrated in pharmacokinetic models that are predictive of the human situation. Examples of drugs metabolized by the microbiome will be discussed in detail to support recommendations from the working group. SIGNIFICANCE STATEMENT Gut microbial metabolism is often neglected in the drug discovery and development process despite growing evidence of drugs' efficacy and safety impacted by their interaction with the microbiome. This paper will detail existing microbiome-related tools covering every stage of drug discovery and development, current progress, and limitations, as well as recommendations to integrate them into the drug discovery and development process.

Personalized Mapping of Drug Metabolism by the Human Gut Microbiome

Systematic mapping of drug metabolism by the human gut microbiome

Mapping human microbiome drug metabolism by gut bacteria and their genes

Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches

Gut Microbiome Integration in Drug Discovery and Development of Small Molecules

A metabolomics pipeline for the mechanistic interrogation of the gut microbiome

The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs

The metabolic effect of gut microbiota on drugs

The Interplay between Gut Microbiota and Oral Medications and Its Impact on Advancing Precision Medicine

An Organ‐on‐chip Platform for Simulating Drug Metabolism along the Gut‐liver Axis

Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine

FROM MICROBIOME TO METABOLOME

Symbiotic gut microbes modulate human metabolic phenotypes

A microbial community cultured in gradient hydrogel for investigating gut microbiome‐drug interaction and guiding therapeutic decisions

The Influence of Gut Microbiota on Drug Metabolism and Toxicity.

Identifying and Filling the Chemobiological Gaps of Gut Microbial Metabolites

Discovery of Drug Candidates for Specific Human Disease Based on Natural Products of Gut Microbes

Human Gut Microbiota and Drug Metabolism

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study

Advances in the integration of metabolomics and metagenomics for human gut microbiome and their clinical applications

Large-scale metabolic interaction network of the mouse and human gut microbiota